Evidence map›Paper›PMID 36590902›Full record

ArticleiScience2023

Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles.

Emma Touizer, Aljawharah Alrubayyi, Rosemarie Ford, Noshin Hussain, Pehuén Pereyra Gerber, Hiu-Long Shum, Chloe Rees-Spear, Luke Muir, Ester Gea-Mallorquí, Jakub Kopycinski and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors.

Emma TouizerInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
Aljawharah AlrubayyiInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
Rosemarie FordInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
Noshin HussainInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
Pehuén Pereyra GerberCambridge Institute of Therapeutic Immunology and Infectious Disease, Department of Medicine, University of Cambridge, Cambridge, UK.
Hiu-Long ShumInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
Chloe Rees-SpearInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
Luke MuirInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
Ester Gea-MallorquíNuffield Department of Medicine, University of Oxford, Oxford, UK.
Jakub KopycinskiNuffield Department of Medicine, University of Oxford, Oxford, UK.
Dylan JankovicInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
Anna Jeffery-SmithInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
Christopher L PinderInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
Thomas A FoxInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
Ian WilliamsMortimer Market Centre, Department of HIV, Central and North West London NHS Trust, London, UK.
Claire MullenderInstitute for Global Health, University College London, London, UK.
Irfaan MaanMortimer Market Centre, Department of HIV, Central and North West London NHS Trust, London, UK.
Laura WatersMortimer Market Centre, Department of HIV, Central and North West London NHS Trust, London, UK.
Margaret JohnsonInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
Sara MadgeThe Ian Charleson Day Centre, Royal Free Hospital NHS Foundation Trust, London, UK.
Michael YouleInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
Tristan J BarberInstitute for Global Health, University College London, London, UK.
Fiona BurnsInstitute for Global Health, University College London, London, UK.
Sabine KinlochInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
Sarah Rowland-JonesNuffield Department of Medicine, University of Oxford, Oxford, UK.
Richard GilsonMortimer Market Centre, Department of HIV, Central and North West London NHS Trust, London, UK.
Nicholas J MathesonCambridge Institute of Therapeutic Immunology and Infectious Disease, Department of Medicine, University of Cambridge, Cambridge, UK.
Emma MorrisInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
Dimitra PeppaInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
Laura E McCoyInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.

Funding

Exploiting Natural Killer cells in HIV/HBV co-infection to achieve eradicationR01AI155182 · NIAID · UNIVERSITY OF OXFORD · PI PEPPA, DIMITRA · 2020 to 2024
$1.9M
Medical Research Council MC_PC_20060Medical Research Council MR/R008698/1Medical Research Council MR/T032413/1Medical Research Council MR/W020556/1NIAID NIH HHS R01 AI155182
6 · The paper itself

Abstract

We assessed a cohort of people living with human immunodeficiency virus (PLWH) (n = 110) and HIV negative controls (n = 64) after 1, 2 or 3 SARS-CoV-2 vaccine doses. At all timepoints, PLWH had significantly lower neutralizing antibody (nAb) titers than HIV-negative controls. We also observed a delayed development of neutralization in PLWH that was underpinned by a reduced frequency of spike-specific memory B cells (MBCs). Improved neutralization breadth was seen against the Omicron variant (BA.1) after the third vaccine dose in PLWH but lower nAb responses persisted and were associated with global MBC dysfunction. In contrast, SARS-CoV-2 vaccination induced robust T cell responses that cross-recognized variants in PLWH. Strikingly, individuals with low or absent neutralization had detectable functional T cell responses. These PLWH had reduced numbers of circulating T follicular helper cells and an enriched population of CXCR3

Indexed as

ImmunologyVirology

Identifiers

PMID36590902
PMCPMC9788849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.